Table 2.
CYP2B6 516G>T and 983T>C genotypes and plasma nevirapine concentrations
| CYP2B6 | N (%) | Plasma nevirapine | P value |
|---|---|---|---|
| concentration (μg/mL), | |||
| geometric mean (95% CI) | |||
| CYP2B6 516G>T | |||
| GG | 32 (48.5) | 7.95 (6.59-9.60) | |
| GT | 25 (37.9) | 9.18 (7.52-11.20) | |
| TT | 9 (13.0) | 14.33 (9.94-20.67) | |
| TOTAL | 66 | 0.01* | |
| CYP2B6 983T>C | |||
| TT | 53 (80.3) | 8.35 (7.33-9.64) | |
| TC | 13 (19.7) | 12.94 (10.11-16.56) | |
| CC | 0 | ||
| TOTAL | 66 | 0.007* | |
| Phenotypes | |||
| Extensive metabolizers | 24 (36.4) | 6.92 (5.70-8.41) | |
| Intermediate metabolizers | 30 (45.5) | 9.34 (7.78-11.20) | 0.02† |
| Slow metabolizers | 12 (18.2) | 14.76 (11.38-19.19) | <0.0001† |
| TOTAL | 66 | ||
*Comparison across groups using Stata’s qtlsnp command.
†ANOVA comparing either intermediate or slow metabolizers to extensive metabolizers (reference category).